









Markets
/
Stocks
/
nasdaq-xoma
/

XOMA Royalty Corp

XOMA

37.860USD

+0.440+1.18%

Close 09/15, 16:00（ET）Quotes delayed by 15 min

456.68MMarket Cap

LossP/E TTM



XOMA Royalty Corp

37.860

+0.440+1.18%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-15

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

17 / 84

Overall Ranking

97 / 4724

Industry

Media & Publishing

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

69.667

Target Price

+90.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 372.66% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 28.49M.

Undervalued

The company’s latest PE is -26.86, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.87M shares, increasing 4.11% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 638.81K shares of this stock.

Financial Health

Currency: USD Updated：2025-09-15

The company's current financial score is 7.76, which is higher than the Media & Publishing industry's average of 7.31. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 15.91M, representing a year-over-year increase of 967.92%, while its net profit experienced a year-over-year increase of 107.08%.

Score

Industry at a Glance

Previous score

7.76

Change

1.23



Financials

9.59

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.70

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-15

The company’s current valuation score is 1.20, which is lower than the Media & Publishing industry's average of 2.42. Its current P/E ratio is -23.89, which is -74.33% below the recent high of -6.13 and 51.91% above the recent low of -11.49.

Score

Industry at a Glance

Previous score

4.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/84

No Data

Earnings Forecast

Currency: USD Updated：2025-09-15

The company’s current earnings forecast score is 8.00, which is higher than the Media & Publishing industry's average of 7.55. The average price target for XOMA Royalty Corp is 55.00, with a high of 104.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

69.667

Target Price

+90.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

XOMA Royalty Corp

XOMA

Roku Inc

ROKU

Paramount Global

PARA

Live Nation Entertainment Inc

LYV

TKO Group Holdings Inc

TKO

Warner Music Group Corp

WMG

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-15

The company’s current price momentum score is 9.06, which is higher than the Media & Publishing industry's average of 7.78. Sideways: Currently, the stock price is trading between the resistance level at 37.91 and the support level at 26.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.33

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.301

Buy

RSI(14)

75.261

Buy

STOCH(KDJ)(9,3,3)

94.100

Overbought

ATR(14)

1.622

Low Volatility

CCI(14)

128.274

Buy

Williams %R

2.337

Overbought

TRIX(12,20)

1.047

Sell

StochRSI(14)

61.494

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

37.268

Buy

MA10

36.195

Buy

MA20

34.599

Buy

MA50

30.009

Buy

MA100

27.607

Buy

MA200

26.168

Buy

Institutional Confidence

Currency: USD Updated：2025-09-15

The company’s current institutional recognition score is 5.00, which is lower than the Media & Publishing industry's average of 7.45. The latest institutional shareholding proportion is 65.79%, representing a quarter-over-quarter decrease of 1.53%. The largest institutional shareholder is The Vanguard, holding a total of 638.81K shares, representing 5.28% of shares outstanding, with 36.18% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

2.59M

-13.17%

Morgan Stanley Investment Management Inc. (US)

1.10M

+277.18%

Fidelity Management & Research Company LLC

1.04M

-0.16%

The Vanguard Group, Inc.

Star Investors

459.09K

-1.02%

BlackRock Institutional Trust Company, N.A.

490.59K

-1.64%

Opaleye Management Inc.

253.04K

+1.22%

Geode Capital Management, L.L.C.

186.67K

+2.46%

Woodline Partners LP

168.55K

+7.86%

State Street Global Advisors (US)

144.73K

+0.14%

Stonepine Capital Management, LLC

129.81K

+3.27%

Risk Assessment

Currency: USD Updated：2025-09-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Media & Publishing domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.83, which is lower than the Media & Publishing industry's average of 4.22. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.